|Other Accession||P84087, P84086, P84088|
|Other Names||Complexin-2, Complexin II, CPX II, Synaphin-1, CPLX2|
|Target/Specificity||The synthetic peptide sequence is selected from aa 51-63 of HUMAN CPLX2|
|Format||Synthetic peptide was lyophilized with 100% acetonitrile and is supplied as a powder. Reconstitute with 0.1 ml DI water for a final concentration of 1 mg/ml.|
|Storage||Maintain refrigerated at 2-8°C for up to 6 months. For long term storage store at -20°C.|
|Precautions||This product is for research use only. Not for use in diagnostic or therapeutic procedures.|
|Function||Negatively regulates the formation of synaptic vesicle clustering at active zone to the presynaptic membrane in postmitotic neurons. Positively regulates a late step in exocytosis of various cytoplasmic vesicles, such as synaptic vesicles and other secretory vesicles. Also involved in mast cell exocytosis (By similarity).|
|Cellular Location||Cytoplasm, cytosol. Note=Enriched at synaptic-releasing sites in mature neurons.|
|Tissue Location||Nervous system. In hippocampus and cerebellum, expressed mainly by excitatory neurons. Down-regulated in brain cortex from patients suffering from Huntington disease, bipolar disorder or major depression. Down-regulated in cerebellum from patients with schizophrenia.|
firstname.lastname@example.org, and receive a free "I Love Antibodies" mug.
Provided below are standard protocols that you may find useful for product applications.
Negatively regulates the formation of synaptic vesicle clustering at active zone to the presynaptic membrane in postmitotic neurons. Positively regulates a late step in synaptic vesicle exocytosis. Also involved in mast cell exocytosis (By similarity).
McMahon H.T.,et al.Cell 83:111-119(1995).
Ota T.,et al.Nat. Genet. 36:40-45(2004).
Raevskaya N.M.,et al.Gene 359:127-137(2005).
Harrison P.J.,et al.Lancet 352:1669-1673(1998).
Eastwood S.L.,et al.Brain Res. Bull. 55:569-578(2001).
If you have any additional inquiries please email technical services at email@example.com.